Combination therapy with anti-TNFs and thiopurines does affect drug metabolite levels but it is not associated with body composition in inflammatory bowel disease patients: A cross-sectional study
K. Szántó, Z. Mezei, D. Kata, I. Földesi, T. Nyári, A. Fábián, M. Rutka, R. Bor, A. Bálint, Á. Milassin, Z. Szepes, F. Nagy, K. Palatka, K. Farkas, T. Molnár
{"title":"Combination therapy with anti-TNFs and thiopurines does affect drug metabolite levels but it is not associated with body composition in inflammatory bowel disease patients: A cross-sectional study","authors":"K. Szántó, Z. Mezei, D. Kata, I. Földesi, T. Nyári, A. Fábián, M. Rutka, R. Bor, A. Bálint, Á. Milassin, Z. Szepes, F. Nagy, K. Palatka, K. Farkas, T. Molnár","doi":"10.33570/ceujgh.7.4.164","DOIUrl":null,"url":null,"abstract":"In this cross-sectional, real-life study we have investigated the potential association between 6-thioguanine nucleotide (6-TGN) and anti-TNF [infliximab (IFX), adalimumab (ADA)], anti-drug antibody levels and body composition parameters. Based on our results thiopurine and anti-TNF combination therapy resulted in decreased antibody formation in IFX-treated patients. AZA-ADA-treated patients showed increased anti-TNF drug concentrations, regardless of antibody formation. Drug metabolites did not correlate with body composition parameters.","PeriodicalId":103444,"journal":{"name":"Central European Journal of Gastroenterology and Hepatology","volume":"25 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Central European Journal of Gastroenterology and Hepatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33570/ceujgh.7.4.164","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
In this cross-sectional, real-life study we have investigated the potential association between 6-thioguanine nucleotide (6-TGN) and anti-TNF [infliximab (IFX), adalimumab (ADA)], anti-drug antibody levels and body composition parameters. Based on our results thiopurine and anti-TNF combination therapy resulted in decreased antibody formation in IFX-treated patients. AZA-ADA-treated patients showed increased anti-TNF drug concentrations, regardless of antibody formation. Drug metabolites did not correlate with body composition parameters.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
